Regina Mendrzyk
Immatics Biotechnologies (Germany)(DE)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Research and Treatments, Biomedical Ethics and Regulation, Immunotherapy and Immune Responses, Virus-based gene therapy research
Most-Cited Works
- → Actively personalized vaccination trial for newly diagnosed glioblastoma(2018)910 cited
- → Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival(2012)780 cited
- → IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial(2016)214 cited
- → Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial(2025)29 cited
- → 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC(2015)20 cited
- → 959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial(2021)17 cited
- → IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC.(2011)16 cited
- → Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma(2019)15 cited
- → Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer(2023)13 cited
- → Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors(2023)12 cited